Ranbaxy Laboratories Limited (Ranbaxy) today announced its entry into the Chyawanprash segment, launching its sugar-free product under the Brand name ‘Chyawan Active’. The product marketed by Ranbaxy’s Global Consumer Healthcare division, will be initially introduced in North India (Delhi, UP, Punjab and Bihar) and later in other parts of the country.

Ranbaxy’s ‘Chyawan Active’ is an Ayurvedic Proprietary Medicine developed by the Company’s Herbal Drug Research team. The product has been manufactured using a novel formulation technology which not only preserves all the benefits of Classical Ayurvedic Chyawanprash, but also ensures a great taste, without any added sugar.

Commenting on the launch of the product, Mr. Malvinder Mohan Singh, CEO & MD, Ranbaxy, said, “The introduction of Ranbaxy’s ‘Chyawan Active’ heralds our entry into the Chywanprash segment. It has always been our endeavour to offer quality, safe, efficacious and innovative solutions to consumers. With life-style related diseases on the rise, ‘Chyawan Active’ offers an excellent nutritional format for the entire family, especially to the health & calorie conscious individuals, diabetics, obese and overweight people.”

It is estimated that India houses more than 40 million diabetic patients; has a male population of over 12% and a female population of above 16% in the obese/overweight category. This phenomenon is alarmingly being witnessed amongst children & adolescents as well. While, Traditional Chyawanprash contains almost 50-60% added sugar, Ranbaxy’s ‘Chyawan Active’ does not have any added sugar, thereby making it a healthy, low calorie alternative for the existing consumers of chyawanprash.

The Chyawanprash segment has a market size of around Rs. 250 crores and saw a growth of more than 15% in value and volume terms in 2006-07. Innovations are likely to drive the market, which still has a low market penetration of about 4%.

Sourced From: Ranbaxy Laboratories Ltd

Tags: calls, daytrading, free calls, intraday, tips

Similar Posts:

• Ranbaxy in marketing pact with BioPro Pharma
• Ranbaxy gets approval for Valganciclovir Hydrochloride tabs
• Ranbaxy wins UK SFO case
• Ranbaxy gets approval to mfg,mkt Cefuroxime Axetil
• Ranbaxy & Daiichi Sankyo confirm deal is binding & final